Lung Cancer Program (Project-009)

摘要：肺癌计划(LCP) 肺癌计划(LCP)是一个跨学科的计划，成员涵盖基础、翻译、 临床和基于人群的学科。LCP研究主要集中在三个主题上：1)新疗法 靶向治疗的靶点和合理组合；2)肺癌的炎症；3)早期发现 以及肺癌的风险预测。在这些中心主题中，LCP的具体目标是：1)界定 促进肺癌发生发展的分子途径；2)改善肺癌的治疗 癌症；3)确定肺癌的高危人群；以及4)改进肺癌的早期发现。这个 LCP致力于提高对肺癌生物学和遗传学的基本理解，并将其应用于 将知识转化为翻译研究目标。目前在LCP中活跃的临床试验针对的是 小细胞和非小细胞肺癌，探索新的治疗策略和新的 组合。只要有可能，由研究人员发起的基于基础研究发现的新试验 都被实施了。LCP积极参与设计和实施国家肺癌临床试验， 包括由联盟(前ACOSOG和CALGB)、东方合作肿瘤学 集团-ACRIN(前身为ECOG)和肺癌突变联盟(LCMC)。LCP维护一个 是全国领先和最大的胸镜手术中心之一，并启动了临床方案以开发 并评估有前景的新疗法，如电视胸镜手术，射频消融术， 以及其他微创外科技术。LCP有30名成员，代表11个部门 匹兹堡大学的两所学校。该计划的成员目前每年可获得总计530万美元 直接资助，包括来自NCI的130万美元和其他同行审查赠款支持的250万美元。LCP是 NCI肺癌卓越研究专业项目(孢子)的所在地，这是第一个 2000年获得资助，并在本CCSG供资周期内完成了第二次竞争性续签。此外, LCP成员每年从“非同行评审”资助机制中获得150万美元。在2010年1月之间 到2014年4月，LCP成员已经撰写了300多篇与癌症相关的出版物，其中50%是由 方案内，38%来自方案间协作。大约45%的论文 代表与外部调查人员的合作。UPCI支持，包括临床协议和数据 管理和共享资源，特别是动物设施、生物统计设施、癌症 生物信息学服务，癌症基因组学设施，癌症药代动力学和药物动力学设施， 癌症蛋白质组学设备，细胞和组织成像设备，细胞计数设备，免疫监测和 细胞产品实验室，活体成像设备，研究药物服务，组织和研究 病理学服务促进和加强LCP研究。

Abstract: Lung Cancer Program (LCP) The Lung Cancer Program (LCP) is an interdisciplinary program with members spanning basic, translational, clinical, and population-based disciplines. LCP research is focused on three main themes: 1) new therapeutic targets and rational combinations of targeted therapies; 2) inflammation in lung cancer; and 3) early detection and risk prediction for lung cancer. Within these central themes, the specific aims of the LCP are to: 1) define molecular pathways that contribute to lung cancer development and progression; 2) improve therapy for lung cancer; 3) identify individuals at high risk for lung cancer; and 4) improve early detection of lung cancer. The LCP works to improve the basic understanding of lung cancer biology and genetics and to apply this knowledge to translational research goals. Clinical trials currently active in the LCP target the continuum of small cell as well as non-small cell lung cancer, exploring both new treatment strategies and novel combinations. Wherever possible, new investigator-initiated trials based on discoveries from basic research are implemented. The LCP is active in design and implementation of national clinical trials for lung cancer, including those sponsored by the Alliance (formerly ACOSOG and CALGB), Eastern Cooperative Oncology Group-ACRIN (formerly ECOG), and the Lung Cancer Mutation Consortium (LCMC). The LCP maintains one of the leading and largest thorascopic surgery centers in the nation and initiates clinical protocols to develop and evaluate promising new treatments, such as video-assisted thorascopic surgery, radiofrequency ablation, and other minimally invasive surgical techniques. The LCP has 30 members, representing 11 departments in 2 schools at the University of Pittsburgh. Members of the Program currently receive a total of $5.3 M in annual direct funding, including $1.3 M from the NCI and $2.5 M in other peer-reviewed grant support. The LCP is home to an NCI Specialized Program of Research Excellence (SPORE) in Lung Cancer, which was first funded in 2000 and completed its second competitive renewal during this CCSG funding cycle. In addition, LCP members receive $1.5 M annually from “non-peer reviewed” grant mechanisms. Between January 2010 and April 2014, LCP members have authored over 300 cancer-related publications, of which 50% resulted from intra-programmatic and 38% from inter-programmatic collaborations. Approximately 45% of the papers represent collaborations with external investigators. UPCI support, including Clinical Protocol and Data Management and Shared Resources, specifically the Animal Facility, Biostatistics Facility, Cancer Bioinformatics Services, Cancer Genomics Facility, Cancer Pharmacokinetics and Pharmacodynamics Facility, Cancer Proteomics Facility, Cell and Tissue Imaging Facility, Cytometry Facility, Immunological Monitoring and Cellular Products Laboratory, In Vivo Imaging Facility, Investigational Drug Services, and Tissue and Research Pathology Services facilitates and enhances LCP research.